Reata’s inventory practically triples after FDA approves rare-disease drug amid uncertainty about strategy to neuroscience remedies

The U.S. Food and Drug Administration on Tuesday accredited Reata Pharmaceuticals Inc.’s remedy for Friedreich’s ataxia, a uncommon inherited illness that causes injury to the nervous system.

Reata’s RETA inventory jumped greater than 180% in after-hours buying and selling, after being halted upfront of the FDA’s determination.

The drug, omaveloxolone, is now…